BR9713535A - alpha-2-adrenoceptor tagonists - Google Patents

alpha-2-adrenoceptor tagonists

Info

Publication number
BR9713535A
BR9713535A BR9713535A BR9713535A BR9713535A BR 9713535 A BR9713535 A BR 9713535A BR 9713535 A BR9713535 A BR 9713535A BR 9713535 A BR9713535 A BR 9713535A BR 9713535 A BR9713535 A BR 9713535A
Authority
BR
Brazil
Prior art keywords
hydrogen
alpha
alkylthio
alkylamino
tagonists
Prior art date
Application number
BR9713535A
Other languages
Portuguese (pt)
Inventor
Thomas Lee Cupps
Sophie Eva Bogdan
Raymond Todd Henry
Russel James Sheldon
William Lee Seibel
Jeffrey Joseph Ares
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BR9713535A publication Critical patent/BR9713535A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)

Abstract

EPTOR"<D>. Esta invenção envolve composto possuindo a estrutura (I) onde: a) R~ 1~ é hidrogênio; ou alquila; b) R~ 2~ é hidrogênio; alquila ou nenhum; c) R~ 3~ é selecionado de hidrogênio; C~ 1~-C~ 3~; C~ 1~-C~ 3~ alquiltio ou alcóxi; C~ 1~-C~ 3~ alquilamino ou C~ 1~-C~ 3~ dialquilamino; ciano; e hacanila não-substituída, alquenila ou alquinila; cicloalcanila, cicloalquenila; C~ 1~-C~ 3~ alquiltioiano; amino; C~ 1~-C~ 3~ alquilamino ou C~ 1~-C~ 3um, ligação (a) é uma ligação dupla; f) o composto não é 7-bromo--6-(2-imidazolinilamino)indazol; e enantiómeros, isómeros ópticos, estereoisómeros, diastereómeros, tautómeros, sais de adição, amidas icas contendo tais novos compostos e o uso de taislados por alfa-2-adrenoceptores.EPTOR "<D>. This invention involves a compound having the structure (I) where: a) R ~ 1 ~ is hydrogen; or alkyl; b) R ~ 2 ~ is hydrogen; alkyl or none; c) R ~ 3 ~ is selected from hydrogen; C ~ 1 ~ -C ~ 3 ~; C ~ 1 ~ -C ~ 3 ~ alkylthio or alkoxy; C ~ 1 ~ -C ~ 3 ~ alkylamino or C ~ 1 ~ -C ~ 3 ~ dialkylamino; cyano ; and unsubstituted hacanyl, alkenyl or alkynyl; cycloalkyl, cycloalkenyl; C ~ 1 ~ -C ~ 3 ~ alkylthio; amino; C ~ 1 ~ -C ~ 3 ~ alkylamino or C ~ 1 ~ -C ~ 3um, bond ( a) is a double bond; f) the compound is not 7-bromo - 6- (2-imidazolinylamino) indazole; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, single amides containing such new compounds and the use of such targets by alpha-2-adrenoceptors.

BR9713535A 1996-11-25 1997-11-21 alpha-2-adrenoceptor tagonists BR9713535A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3174096P 1996-11-25 1996-11-25
PCT/US1997/020551 WO1998023609A1 (en) 1996-11-25 1997-11-21 2-imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonists

Publications (1)

Publication Number Publication Date
BR9713535A true BR9713535A (en) 2000-03-21

Family

ID=21861136

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713535A BR9713535A (en) 1996-11-25 1997-11-21 alpha-2-adrenoceptor tagonists

Country Status (20)

Country Link
EP (1) EP0944620A1 (en)
JP (1) JP2001506599A (en)
KR (1) KR20000069104A (en)
CN (1) CN1244864A (en)
AR (1) AR010643A1 (en)
AU (1) AU5433998A (en)
BR (1) BR9713535A (en)
CA (1) CA2272644A1 (en)
CO (1) CO4910166A1 (en)
CZ (1) CZ183999A3 (en)
HU (1) HUP9904660A3 (en)
ID (1) ID22676A (en)
IL (1) IL130067A0 (en)
NO (1) NO992502L (en)
NZ (1) NZ335882A (en)
PE (1) PE47099A1 (en)
SK (1) SK69699A3 (en)
TR (1) TR199901542T2 (en)
WO (1) WO1998023609A1 (en)
ZA (1) ZA9710576B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908175D0 (en) * 1999-04-09 1999-06-02 Lilly Co Eli Method of treating neurological disorders
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
EP2226315A4 (en) 2007-12-28 2012-01-25 Carna Biosciences Inc 2-aminoquinazoline derivative
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
CN112538074A (en) * 2020-12-24 2021-03-23 艾希尔（深圳）药物研发有限公司 Preparation method of debrominated impurities of brimonidine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH641782A5 (en) * 1978-12-07 1984-03-15 Siegfried Ag 1H- and 2H-indazole derivatives
US4526898A (en) * 1980-09-05 1985-07-02 Siegfried Aktiengesselschaft Antihypertensive 4-(2-imidazolin-2-yl-amino)-2-methyl-indazole
ES2150546T3 (en) * 1993-12-17 2000-12-01 Procter & Gamble COMPOUNDS OF 6- (2-IMIDAZOLINYLAMINE) QUINOXALINE USEFUL AS ALPHA-2-ADRENOCEPTOR AGONISTS.
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists

Also Published As

Publication number Publication date
HUP9904660A2 (en) 2000-06-28
CO4910166A1 (en) 2000-04-24
PE47099A1 (en) 1999-06-12
NO992502D0 (en) 1999-05-25
CN1244864A (en) 2000-02-16
TR199901542T2 (en) 2000-01-21
KR20000069104A (en) 2000-11-25
ID22676A (en) 1999-12-09
CA2272644A1 (en) 1998-06-04
ZA9710576B (en) 1998-09-16
SK69699A3 (en) 2000-06-12
WO1998023609A1 (en) 1998-06-04
NO992502L (en) 1999-07-26
AU5433998A (en) 1998-06-22
CZ183999A3 (en) 1999-11-17
NZ335882A (en) 2000-12-22
HUP9904660A3 (en) 2002-02-28
JP2001506599A (en) 2001-05-22
AR010643A1 (en) 2000-06-28
IL130067A0 (en) 2000-02-29
EP0944620A1 (en) 1999-09-29

Similar Documents

Publication Publication Date Title
ATE227567T1 (en) PREPARATIONS FOR INHIBITING BONE RESORPTION MEDIATED BY OSTEOCLASTS
DK0792641T3 (en) Use of estrogen antagonists and estrogen agonists to inhibit pathological conditions
HU229457B1 (en) Fungicidal n2-phenylamidine derivatives, intermediates and use thereof
BR9907300A (en) Substituted oxoaza-heterocyclyl factor x inhibitors
ATE307119T1 (en) BICYCLIC PROTEIN FARNESYL TRANSFERASE INHIBITORS
IT1283588B1 (en) SYNERGIC MIXTURE OF STABILIZING AGENTS
NO180538C (en) N-sulfonyl-2-oxoindole derivatives having affinity for vasopressin and / or ocytocin receptors, pharmaceutical compositions containing them and intermediates in the preparation of the derivatives
HRP20000469B1 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
MXPA04004457A (en) Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators.
NO991494L (en) &lt;beta&gt; -sulfonylhydroxamic acids as matrix metalloproteinase inhibitors
ES2193154T3 (en) PROCEDURE FOR THE PREPARATION OF 9-DEOXOTAXANS.
BR9713542A (en) 2 - imidazolinylaminoindole compounds useful as alpha - 2 - adrenoceptor agonists
HUP0100732A2 (en) Synergetic fungicidal composition comprising amide compound and azole derivative and its use
UA27220C2 (en) method for obtaining derivatives of 1-phenylimidazoline-2,5-dione
NZ514576A (en) Substituted 3-cyano-[1.7], [1.5], and [1.8]- naphthyridine inhibitors of tyrosine kinases
BR9713535A (en) alpha-2-adrenoceptor tagonists
BR9713537A (en) as alpha-2-adrenoreceptor agonists
NZ336450A (en) 3-aminocarbonyl / 3-aminothiocarbonyl-substituted 2-benzoyl- cyclohexan-1,3-diones with herbicidal effect
HUT73231A (en) Pharmaceutical compositions with 17-beta-monosubstituted-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones for treatment of chronic prostatitis
AU6876896A (en) Carbamoylcarboxamides
DE69910574D1 (en) PYRAZOLO [1,5-A] TRIAZINE AS CRF ANTAGONISTS
UA26459C2 (en) INHIBITOR OF INFLUENCE OF AMYLOID PROTEINS
DE69827614D1 (en) quinoxalinediones
ATE236901T1 (en) HERBICIDE SUBSTITUTED THIENOCYCLOALK(EN)YLAMINO-1,3,5-TRIAZINE
DK0667863T3 (en) 2-Perhaloalkyl-substituted benzimidazoles, their preparation and their use as pesticides

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A,7A E 8A ANUIDADE.